Back to Search
Start Over
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
- Source :
-
Molecular cancer therapeutics [Mol Cancer Ther] 2005 Jun; Vol. 4 (6), pp. 901-9. - Publication Year :
- 2005
-
Abstract
- PRIMA-1 (p53 reactivation and induction of massive apoptosis) is a chemical compound that was originally identified as a selective mutant p53-dependent growth suppressor by screening a library of low-molecular-weight compounds. However, its mechanism of action is unknown. In this study, we examined toxicity of PRIMA-1 to three premalignant human colorectal adenoma cell lines (RG/C2, BR/C1, and AA/C1) and four colorectal carcinoma cell lines (DLD-1, SW480, LOVO, and HCT116) and its mechanism of action. It selectively induced apoptosis only in the mutant p53 premalignant and malignant colon cell lines, but was not toxic to the wild-type p53 premalignant and malignant colon cell lines. Using stable transfectants of temperature-sensitive p53 mutant Ala(143) in null p53 H1299 lung cancer cells, we found that PRIMA-1 induced significantly more apoptosis in cells with mutant p53 conformation (37 degrees C) than the wild-type p53 conformation (32.5 degrees C). Cell cycle analysis indicated that its inhibition of cell growth was correlated with induction of G(2) arrest. Western blot analysis showed PRIMA-1 increased p21 and GADD45 expression selectively in the mutant p53 cells. However, Fas, Bcl-2 family proteins, and caspases were not involved in PRIMA-1-induced cell death. The c-Jun-NH(2)-kinase (JNK) inhibitor SP 600125, but not p38 mitogen-activated protein kinase inhibitor SB 203580 or extracellular signal-regulated kinase inhibitor PD 98059, blocked PRIMA-1-induced apoptosis. Transfection with a dominant-negative phosphorylation mutant JNK, but not a dominant-negative p38 or wild-type JNK, inhibited PRIMA-1-induced cell death, suggesting that the JNK pathway plays an important role in PRIMA-1-induced apoptosis. PRIMA-1 is a highly selective small molecule toxic to p53 mutant cells and may serve as a prototype for the development of new p53-targeting agents for therapy of premalignant and malignant cells.
- Subjects :
- Cell Line
Cell Transformation, Neoplastic genetics
Cell Transformation, Neoplastic metabolism
Cell Transformation, Neoplastic pathology
Colonic Neoplasms metabolism
Colonic Neoplasms pathology
Humans
JNK Mitogen-Activated Protein Kinases antagonists & inhibitors
JNK Mitogen-Activated Protein Kinases genetics
Lung Neoplasms metabolism
Lung Neoplasms pathology
Neoplasms genetics
Neoplasms pathology
Precancerous Conditions genetics
Protein Kinase Inhibitors pharmacology
RNA, Messenger genetics
RNA, Messenger metabolism
Temperature
Apoptosis drug effects
Aza Compounds pharmacology
Bridged Bicyclo Compounds, Heterocyclic pharmacology
JNK Mitogen-Activated Protein Kinases metabolism
Neoplasms metabolism
Precancerous Conditions metabolism
Signal Transduction drug effects
Tumor Suppressor Protein p53 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1535-7163
- Volume :
- 4
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Molecular cancer therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 15956247
- Full Text :
- https://doi.org/10.1158/1535-7163.MCT-04-0206